MedTrace Logo

Ultraprocessed Foods in Colombia

NCT07528443 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1960

Last updated 2026-04-14

No results posted yet for this study

Summary

The study seeks to examine how characters on packaging and warning labels affect purchase intentions and risk perception among children aged 12 to 17 in Colombia and, examine whether characters' presence weakens or reduces the perceived message effectiveness of the warning labels' impact. This will be a 2x2 between-subjects experiment manipulating presence or absence of characters and presence or absence of warning labels. Participants will be randomly assigned to 1 of 4 conditions in an online survey programmed in Qualtrics.

Conditions

Interventions

BEHAVIORAL

Warning label

Participants will view images of three products containing octagonal warning labels.

BEHAVIORAL

Barcode control label

Participants will view images of three products containing Barcode control label.

BEHAVIORAL

Character

Participants will view images of three products containing characters.

BEHAVIORAL

Without character

Participants will view images of three products without characters.

Sponsors & Collaborators

  • The Bloomberg Family Foundation, Inc.

    collaborator OTHER

  • Pontificia Universidad Javeriana

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Maria Parra-Murillo · University of North Carolina, Chapel Hill

  • Marissa Hall, PhD · University of North Carolina, Chapel Hill

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Colombia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07528443 on ClinicalTrials.gov